Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.
about
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceHuman obesity and endothelium-dependent responsivenessPPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosisRegulation of oxidative stress and cardioprotection in diabetes mellitus.A systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy.Activation of systemic, but not local, renin-angiotensin system is associated with upregulation of TNF-α during prolonged fasting in northern elephant seal pups.PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.ACE as a mechanosensor to shear stress influences the control of its own regulation via phosphorylation of cytoplasmic Ser(1270)Inflammatory cytokines in diabetic nephropathy.Abundant pleiotropy in human complex diseases and traits.Pleiotropic effects of calcium channel blockers.Metabolic dysfunction in obstructive sleep apnea: A critical examination of underlying mechanismsAlamandine reduces leptin expression through the c-Src/p38 MAP kinase pathway in adipose tissueChronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome?Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.Losartan and ozagrel reverse retinal arteriolar constriction in non-obese diabetic miceHypertension in rheumatoid arthritis.Nebivolol and quinapril reduce p-wave duration and dispersion in hypertensive patients.Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements.Renal dysfunction potentiates foam cell formation by repressing ABCA1.PPARδ binding to heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats.Local bone marrow Renin-Angiotensin system and atherosclerosis.Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management.Oxidative stress and cardiovascular health: therapeutic potential of polyphenols.AT1 antagonists: a patent review (2008 - 2012).Novel RAAS agonists and antagonists: clinical applications and controversies.Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice.New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.Lipotoxicity-Related Hematological Disorders in Obesity.Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension.Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbitsHigh ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.Opposite effect of angiotensin receptor blockade on CXCL8 production and CXCR1/2 expression of angiotensin II-treated THP-1 monocytesInteractome of Obesity: Obesidome : Genetic Obesity, Stress Induced Obesity, Pathogenic Obesity Interaction.ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS.Effects of nicotine on the testicular toxicity of streptozotocin-induced diabetic rat: intervention of enalapril.Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
P2860
Q27003277-A587E954-C814-41C1-AA36-473DBBB1AFF1Q27021665-590EF17B-C0DB-4020-ACC9-B0C7F89C3271Q30482025-536918BE-32A9-460B-8B82-31C02FB75BA8Q33572259-E18B7499-6F1E-4517-899D-D9C49F67A995Q33783045-290FB831-0D23-4704-BBD8-B7A66363CAA1Q33817992-B234A965-8D4D-4CBE-999A-CE7E9DC4C930Q33987140-7C5C305D-FD69-4C80-A793-0B6E5E574F10Q34013681-DE0CB47F-A677-4F14-8447-9128CD45A59FQ35133177-878B8BE3-C33C-49D4-95C8-FD17C5F75179Q35542127-5D1BC9F3-7BC2-40B3-8459-D34A553A6141Q36072052-43C94121-5E78-4A2A-8B37-783BCDDA8BA5Q36093354-9387D6A2-414D-43EF-9366-34E31228969AQ36395019-D4A0BD2D-28D3-4DC6-81B3-7F257A6CF784Q36487408-F0F09FA6-94A3-4398-BA0C-1A5379733E5EQ36576477-25A02D9E-8994-4453-AA26-D9006598A247Q36857431-3180DDF8-FFB0-427D-BED0-26AC0C487342Q37158219-FA1C1376-711A-4BD9-9143-0309430C4AD3Q37195973-781F6F44-51E2-4471-9195-82DCA4C2142FQ37281446-B019A3C3-BFE7-4B7A-96EA-1EDDB7779A96Q37319058-80707295-F699-45EB-AB01-B46553C05818Q37326570-C231460C-BA82-4D8C-B376-2034851CA782Q37357219-4DAB330A-994B-40FD-AD56-19A9178E061CQ37631653-5987DBF1-CC39-4AAE-9B6C-B19B21677FE2Q37828412-C97ADDA0-1FD3-446E-8623-DC6292B6827DQ37880077-D2C4703B-828A-401E-9C2B-11ED570DD15CQ38093866-4E05FD0F-20E5-4487-9812-41F455CF1572Q38130756-D3BF11E4-F826-4647-844A-21140500A20BQ38349798-63E97F6C-01FB-4FC8-9798-6DF75B3BA50BQ38476603-EF42B59F-A40D-404C-A2DD-3AA9EF1DE7A7Q38845433-23EF3CEB-5A7D-4DF4-A809-3E92EBD0B453Q39353771-1C4276DB-97E1-4939-B16D-905B31F8744DQ39868931-7F16AF64-8A26-4618-91DE-51127385D442Q40831300-460BE695-7D95-42AF-92AF-407FDA93D2A2Q41807679-B71A489D-A50A-4F1A-B411-C2E90AE089B8Q41881229-68814B24-E68F-43D9-A987-CF9DEC959B9CQ41991835-F8F2A60A-E681-4FDD-856D-198460D22EC8Q43195252-A1049548-25E9-40A8-A14B-718369B31A9CQ43833798-41E64F24-5691-48A3-8673-612C0F7486E8Q44822896-50E2BFA8-FB8D-4DD4-8194-68861D700703Q45154756-029D83E2-B1D8-4CEC-9F3F-5F9295CE84E1
P2860
Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@ast
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@en
type
label
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@ast
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@en
prefLabel
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@ast
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@en
P2093
P2860
P356
P1476
Angiotensin II and inflammatio ...... iotensin II receptor blockade.
@en
P2093
P2860
P2888
P356
10.1038/SJ.JHH.1002101
P577
2006-11-09T00:00:00Z
P5875
P6179
1035210409